Area(s) of interest
Jan Stolk studied medicine at the Free University of Amsterdam where he graduated in 1984. Following completion of his training in pulmonology at the Department of Pulmonology in LUMC he was appointed as chest physician in this department. In 1994 he finished his PhD studies on Defense Strategies in Pulmonary Inflammation. He was the principal investigator of a number of multicenter international clinical trials. Currently, his aim is to continue studying the above mentioned clinical condition with a focus on collecting clinical information over a number of years on cohorts of patients.
Areas of interest
- Alpha-1-antitrypsin deficiency
- Diaphragm paralysis
- Systemic Scleroderma-related lung disease
Jan Stolk is the current chairman of an international network of clinical scientists with a special interest in alpha-1-antitrypsin deficiency. The network, alpha1 international registry, aims to study the pathogenesis of lung and liver disease related to the deficiency. In addition, the network aims to establish new clinical parameters to monitor progression of lung disease and to utilize these newly developed parameters in clinical trials for new drugs for alpha-1-antitrypsin deficiency-related lung disease. By studying sibling pairs with a discordant clinical phenotype of the Pi ZZ genotype of the deficiency, he aims to contribute to a better understanding of the pathogenesis of this condition. In a multidisciplinary team in LUMC, new progression parameters of lung disease such as Perc15 lung density for emphysema and bronchial lumen area for COPD have been developed. Clinical trials for new drugs are a means to provide patients in the Netherlands high standard clinical care and an opportunity to help discover new treatment modalities.
Diaphragm paralysis (uni- or bilateral) as part of neuralgic amyotrophy in adults is a rare acquired condition for which a surgical technique, diaphragm placation, became available some 10 years ago. After reporting initial surgical experience, a multidisciplinary team aims to improve long-term outcome of the surgery.
Recently, systemic scleroderma-related lung disease is being studied in collaboration with the department of Rheumatology of LUMC and three other university medical centers in NL with the aim to identify progression parameters of lung disease.
Leiden University Medical Center
2333 ZA Leiden
Tel: 71 5262950
P.O. Box 9600
2300 RC Leiden